Physician profile
Sheila Kar
NPI 1922143007
$9,892.18
in general payments reported to CMS, 2019-2025
36 companies · $5,282 in 2025
The $5,282 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $120 · 2021: $479 · 2022: $1,029 · 2023: $1,342 · 2024: $955 · 2025: $5,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,710.97 | 2019-2025 | General - Therapies, Wavewriter Alpha Prime 16, General - Ep |
| Bridgebio Pharma, INC. | $1,526.98 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $790.43 | 2020-2025 | |
| Amgen INC. | $684.62 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $516.25 | 2019-2025 | |
| Biosense Webster, INC. | $515.92 | 2023-2025 | Carto 3 |
| Abbott Laboratories | $461.02 | 2022-2025 | Ensite Precision, Perclose Proglide |
| Astrazeneca Pharmaceuticals Lp | $344.31 | 2021-2023 | Farxiga, Brilinta, Breztri |
| Daiichi Sankyo INC. | $326.42 | 2019-2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $309.30 | 2023-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $211.42 | 2020-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.38 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Medtronic, INC. | $143.65 | 2025 | Affera Mapping System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.84 | 2019-2024 | Xifaxan |
| Viiv Healthcare Company | $111.84 | 2023-2024 | Apretude |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $108.80 | 2019 | |
| Heartflow, INC. | $108.66 | 2022-2025 | Ffrct |
| Merck Sharp & Dohme LLC | $90.88 | 2024 | Delstrigo, Pifeltro, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $77.61 | 2023-2025 | |
| Bardy Diagnostics, INC. | $69.68 | 2020-2021 | |
| Exact Sciences Corporation | $62.44 | 2023-2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $49.37 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.17 | 2022 | |
| Janssen Scientific Affairs, LLC | $43.24 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.54 | 2023-2025 | Trintellix |
| Abbvie INC. | $28.24 | 2022 | |
| Lilly USA, LLC | $23.29 | 2024 | Mounjaro |
| Esperion Therapeutics, INC. | $22.83 | 2021 | |
| Glaxosmithkline, LLC. | $22.36 | 2023 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $21.88 | 2019 | |
| Novo Nordisk INC | $21.66 | 2021 | |
| Allergan, INC. | $21.49 | 2019 | |
| Horizon Therapeutics Plc | $18.82 | 2023 | Krystexxa |
| Amarin Pharma, INC. | $17.47 | 2019 | |
| Philips North America LLC | $14.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Kar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.